Earlier in the day, the National Pharmaceutical Pricing Authority (NPPA) had said that prices of around 78 per cent of 'actively used' drugs will remain unaffected after the rollout of the Goods and Services Tax (GST) from midnight tonight.
"Price of drugs where partial increase is expected due to rollout of GST will not be passed on to consumers as NPPA is working out a mechanism in this regard," Chemicals and Fertilisers Minister Ananth Kumar told reporters here.
Kumar reiterated that "prices of life saving drugs and essential drugs rates will come down with reduction in GST rate".
NPPA has already announced provisional ceiling prices of 761 medicines, including anti-cancer, HIV, diabetes and antibiotics, with a majority being reduced ahead of the GST implementation.
These prices will be notified as formal revised ceiling prices immediately after GST notification, NPPA had said in a memorandum earlier this week.
"Prices of approximately 78 per cent of all actively used and traded drugs in the country are going to remain unaffected post GST," NPPA said in a tweet today.
The government has fixed GST rate of 12 per cent on most of the essential drugs as against the current tax incidence of around 9 per cent.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
